Summary:
The study consists of a 25 day treatment period at CBH Health located in Gaithersburg, MD. Inpatient stay of anywhere from 5-21 day followed by outpatient visits. Purpose of the study is to evaluate efficacy, safety and tolerability of intranasal ESKETAMINE.
Qualified Participants Must:
• Ages 18-64
•
Weight 89-276 lbs.
•
Willing to stay inpatient in our clinical research unit (stay of at least 5 days but not to exceed 21 days)
•
Diagnosis of Major Depressive Disorder with CURRENT suicidal ideation
•
Good physical health
•
Historical use of ketamine or any hallucinogens is exclusionary
•
No seizure disorder, strokes or tumor
•
No lifetime history of any psychotic disorder
•
No suicide attempt within the past year
•
Antipsychotics are exclusionary
Qualified Participants May Receive:
Compensation will be provided.